Read + Share
Rowan C. In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at
12 and 52 wk. Ann Intern Med 2023 Sep 5. doi: 10.7326/J23-0069.
PMID: 37665995
|
 |
|
Rowan C. In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at
12 and 52 wk. Ann Intern Med 2023 Sep 5. doi: 10.7326/J23-0069.
PMID: 37665995
|
|
|
|